About Alnylam
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product engine to develop a deep pipeline of drug products to treat a wide array of important diseases
Facts about Alnylam
Facts about Alnylam
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of Alnylam
Here you will find Alnylam Europe AG
Last viewed contents
Three Rivers Pharmaceuticals, LLC - Cranberry Township, PA, USA
ERICHSEN GmbH & Co KG - Hemer, Germany
Celgene Corporation Reviews 2004 Achievements and Announces 2005 Financial Outlook
National Instruments and Agilet Technologies extend functionaltiy, flexibility of analytical instrumentation with LabVIEW
Berufsverband der Deutschen Chirurgen e.V. - Berlin, Germany
BioShield Develops New Solid Form Antimicrobial - BST 1870 To Be Marketed in the $2 Trillion Worldwide Healthcare Sector - BST 1870 Developed to Become FDA Grade Product
Clinical Trials Initiated and Significant Milestone Reached in the Collaboration Between Karo Bio and Merck & Co., Inc.
